Trial Outcomes & Findings for Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients. (NCT NCT00266708)

NCT ID: NCT00266708

Last Updated: 2019-03-01

Results Overview

Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using the Hologic 4500 QDC scanner.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

60 participants

Primary outcome timeframe

month 6 of the treatment

Results posted on

2019-03-01

Participant Flow

Transplant candidates from Montefiore Medical Centre were recruited for the study.

117 transplant candidates were identified as potentially eligible for the study. 57 of the 117 refused to participate and 60 of the candidates signed consent forms. Of the 60 who signed, 18 were either not transplanted or lost to follow-up so only 42 were randomized.

Participant milestones

Participant milestones
Measure
Risedronate
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
subjects received placebo for 1 year Placebo weekly
Overall Study
STARTED
20
22
Overall Study
COMPLETED
16
13
Overall Study
NOT COMPLETED
4
9

Reasons for withdrawal

Reasons for withdrawal
Measure
Risedronate
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
subjects received placebo for 1 year Placebo weekly
Overall Study
No renal function
1
1
Overall Study
Refused biopsy
3
6
Overall Study
Asthma
0
2

Baseline Characteristics

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Risedronate
n=20 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=22 Participants
subjects received placebo for 1 year Placebo weekly
Total
n=42 Participants
Total of all reporting groups
Age, Continuous
42 years
STANDARD_DEVIATION 11 • n=99 Participants
48 years
STANDARD_DEVIATION 14 • n=107 Participants
44.7 years
STANDARD_DEVIATION 12.42 • n=206 Participants
Sex: Female, Male
Female
9 Participants
n=99 Participants
6 Participants
n=107 Participants
15 Participants
n=206 Participants
Sex: Female, Male
Male
11 Participants
n=99 Participants
16 Participants
n=107 Participants
27 Participants
n=206 Participants
Race/Ethnicity, Customized
African American
3 Participants
n=99 Participants
3 Participants
n=107 Participants
6 Participants
n=206 Participants
Race/Ethnicity, Customized
Hispanic
10 Participants
n=99 Participants
11 Participants
n=107 Participants
21 Participants
n=206 Participants
Race/Ethnicity, Customized
White
5 Participants
n=99 Participants
6 Participants
n=107 Participants
11 Participants
n=206 Participants
Race/Ethnicity, Customized
Other
2 Participants
n=99 Participants
2 Participants
n=107 Participants
4 Participants
n=206 Participants
Region of Enrollment
United States
20 participants
n=99 Participants
22 participants
n=107 Participants
42 participants
n=206 Participants
BMD Calcium - Spine
1.01 gm/cm^2
STANDARD_DEVIATION 0.17 • n=99 Participants
1.01 gm/cm^2
STANDARD_DEVIATION 0.17 • n=107 Participants
1.01 gm/cm^2
STANDARD_DEVIATION 0.17 • n=206 Participants
BMD Calcium - Hip
0.90 gm/cm^2
STANDARD_DEVIATION 0.15 • n=99 Participants
0.92 gm/cm^2
STANDARD_DEVIATION 0.17 • n=107 Participants
0.909 gm/cm^2
STANDARD_DEVIATION 0.16 • n=206 Participants
BMD Calcium - Forearm
0.54 gm/cm^2
STANDARD_DEVIATION 0.09 • n=99 Participants
0.61 gm/cm^2
STANDARD_DEVIATION 0.09 • n=107 Participants
0.57 gm/cm^2
STANDARD_DEVIATION 0.09 • n=206 Participants

PRIMARY outcome

Timeframe: month 6 of the treatment

Population: Calculation done on intent-to-treat population

Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using the Hologic 4500 QDC scanner.

Outcome measures

Outcome measures
Measure
Risedronate
n=20 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=22 Participants
subjects received placebo for 1 year Placebo weekly
Bone Mineral Density of Spine at 6 Months
0.98 gm/cm^2
Standard Deviation 0.16
0.97 gm/cm^2
Standard Deviation 0.14

PRIMARY outcome

Timeframe: month 12 of treatment

Population: Calculation done on intent-to-treat population

Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using same Hologic 4500 QDC scanner.

Outcome measures

Outcome measures
Measure
Risedronate
n=20 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=22 Participants
subjects received placebo for 1 year Placebo weekly
Bone Mineral Density of Spine at 12 Months
1.00 gm/cm^2
Standard Deviation 0.18
1.00 gm/cm^2
Standard Deviation 0.18

PRIMARY outcome

Timeframe: month 6 of the treatment

Population: Calculation done on intent-to-treat population

Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.

Outcome measures

Outcome measures
Measure
Risedronate
n=20 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=22 Participants
subjects received placebo for 1 year Placebo weekly
Bone Mineral Density of the Hip at 6 Months
0.88 gm/cm^2
Standard Deviation 0.13
0.86 gm/cm^2
Standard Deviation 0.13

PRIMARY outcome

Timeframe: month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.

Outcome measures

Outcome measures
Measure
Risedronate
n=20 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=22 Participants
subjects received placebo for 1 year Placebo weekly
Bone Mineral Density of the Hip at 12 Months
0.91 gm/cm^2
Standard Deviation 0.13
0.87 gm/cm^2
Standard Deviation 0.15

PRIMARY outcome

Timeframe: month 6 of the treatment

Population: Calculation done on intent-to-treat population

Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.

Outcome measures

Outcome measures
Measure
Risedronate
n=20 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=22 Participants
subjects received placebo for 1 year Placebo weekly
Bone Mineral Density of Forearm at 6 Months
0.57 gm/cm^2
Standard Deviation 0.11
0.58 gm/cm^2
Standard Deviation 0.11

PRIMARY outcome

Timeframe: month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.

Outcome measures

Outcome measures
Measure
Risedronate
n=20 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=22 Participants
subjects received placebo for 1 year Placebo weekly
Bone Mineral Density of Forearm at 12 Months
0.55 gm/cm^2
Standard Deviation 0.12
0.58 gm/cm^2
Standard Deviation 0.09

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Bone Volume is the percentage of total volume occupied by calcified bone. Percent Bone volume is calculated as Bone Volume (BV) divided by Tissue Volume (TV), where TV is bone plus marrow.

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Percent Bone Volume (BV/TV)
Baseline
10.7 percent
Standard Deviation 6
13.3 percent
Standard Deviation 9
Bone Histomorphometry - Percent Bone Volume (BV/TV)
month 12
11.3 percent
Standard Deviation 5
9.7 percent
Standard Deviation 4

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. The ends of certain bones, known as cancellous bones, are actually not solid but are full of holes that are connected to each other by thin rods and plates of bone tissue known as trabeculae. Trabeculae of bone provide structural support to the spongy bone found at the ends of long bones. Trabeculae Trabecular Thickness (TbTh), a structural parameter, is the distance across individual trabecula.

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Trabecular Thickness (TbTh)
Baseline
72.6 micron
Standard Deviation 17
90.9 micron
Standard Deviation 39
Bone Histomorphometry - Trabecular Thickness (TbTh)
month 12
72.1 micron
Standard Deviation 28
62.2 micron
Standard Deviation 20

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Mineralized Bone Volume is the percentage of Bone Volume consisting of mineralized bone. Percent Mineralized Bone Volume is calculated as Mineralized Bone Volume (MdV) divided by Bone Volume (BV).

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Percent Mineralized Bone Volume (MdV/BV)
Baseline
95 percent
Standard Deviation 3
95 percent
Standard Deviation 4
Bone Histomorphometry - Percent Mineralized Bone Volume (MdV/BV)
month 12
92 percent
Standard Deviation 7
96 percent
Standard Deviation 6

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Bone mineralization is the process of laying down minerals on the matrix of the bone, with calcium and phosphorus as the most abundant minerals. Mineralized Bone Volume (MdV) is the percentage of mineralized bone tissue.

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Mineralized Bone Volume (MdV)
Baseline
1.2 percent
Standard Deviation 0.4
1.3 percent
Standard Deviation 1
Bone Histomorphometry - Mineralized Bone Volume (MdV)
month 12
1.2 percent
Standard Deviation 0.5
1.0 percent
Standard Deviation 0.5

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of bone that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Bone Volume (BV).

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Percent Osteoid Volume Relative to Bone Volume(OV/BV)
Baseline
4.1 percent
Standard Deviation 2.6
4.6 percent
Standard Deviation 3.4
Bone Histomorphometry - Percent Osteoid Volume Relative to Bone Volume(OV/BV)
month 12
8.7 percent
Standard Deviation 7.2
4.9 percent
Standard Deviation 5

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of tissue (bone + marrow) that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Tissue Volume (TV).

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Percent Osteoid Volume Relative to Tissue Volume (OV/TV)
Baseline
0.49 percent
Standard Deviation 0.4
0.58 percent
Standard Deviation 0.58
Bone Histomorphometry - Percent Osteoid Volume Relative to Tissue Volume (OV/TV)
month 12
0.90 percent
Standard Deviation 0.8
0.51 percent
Standard Deviation 0.8

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of bone surface that consists of unmineralized bone. It is equal to Osteoid Surface (OS) divided by Bone Surface (BS).

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Percent Osteoid Surface Relative to Bone Surface (OS/BS)
Baseline
23 percent
Standard Deviation 18
15 percent
Standard Deviation 8
Bone Histomorphometry - Percent Osteoid Surface Relative to Bone Surface (OS/BS)
month 12
24 percent
Standard Deviation 27
14 percent
Standard Deviation 10

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone mass is a balance between the osteoblasts (OB) that form the bone and cells called osteoclasts (OC) that break down the bone. The reported values indicate the percent of bone surface (BS) that is made up of osteoblasts (OB).

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Percent Osteoblasts Relative to Bone Surface (OB/BS)
Baseline
2.3 percent
Standard Deviation 3
1.3 percent
Standard Deviation 1.3
Bone Histomorphometry - Percent Osteoblasts Relative to Bone Surface (OB/BS)
month 12
1.23 percent
Standard Deviation 1.6
0.75 percent
Standard Deviation 0.76

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secrete digestive enzymes that break up or dissolve the bone tissue. Bone mass is a balance between the osteoblasts (OB) cells that form the bone and the osteoclasts (OC) cells that break down the bone. The reported values indicate the percent of bone surface (BS) that consists of osteoclasts (OC).

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=16 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Percent Osteoclasts Relative to Bone Surface (OC/BS)
Baseline
1.5 percent
Standard Deviation 1.9
0.97 percent
Standard Deviation 1.2
Bone Histomorphometry - Percent Osteoclasts Relative to Bone Surface (OC/BS)
month 12
0.28 percent
Standard Deviation 0.43
0.68 percent
Standard Deviation 1.23

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secret digestive enzymes tha break up or dissolve the bone tissue. An eroded surface (ES) is the surface of the lacuna ( a cavity or depression in the bone) generated by an active OC. The reported values indicate the percent of eroded surface relative to bone surface (BS).

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Percent Eroded Surface Relative to Bone Surface (ES/BS)
Baseline
9 percent
Standard Deviation 11
1.36 percent
Standard Deviation 1.7
Bone Histomorphometry - Percent Eroded Surface Relative to Bone Surface (ES/BS)
month 12
2.7 percent
Standard Deviation 3
0.82 percent
Standard Deviation 1.4

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone formation rate (BFR) indicates how much of the bone is actively mineralizing; it is determined by the number of active OB and the average work of each OB.

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Bone Formation Rate
Baseline
0.02 micron/day
Standard Deviation 0.05
0.04 micron/day
Standard Deviation 0.1
Bone Histomorphometry - Bone Formation Rate
month 12
0.10 micron/day
Standard Deviation 0.16
0.05 micron/day
Standard Deviation 0.06

SECONDARY outcome

Timeframe: Baseline and month 12 of the treatment

Population: Calculation done on intent-to-treat population

Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the Osteoid Volume (OV), the volume of bone that consists of unmineralized bone.

Outcome measures

Outcome measures
Measure
Risedronate
n=16 Participants
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=13 Participants
subjects received placebo for 1 year Placebo weekly
Bone Histomorphometry - Osteoid Volume (OV)
Baseline
0.06 micron^3
Standard Deviation 0.04
0.06 micron^3
Standard Deviation 0.06
Bone Histomorphometry - Osteoid Volume (OV)
month 12
0.10 micron^3
Standard Deviation 0.09
0.03 micron^3
Standard Deviation 0.02

Adverse Events

Risedronate

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Risedronate
n=20 participants at risk
subjects received Risedronate for one year Risedronate 35 Mg: risedronate 35 mg weekly
Placebo
n=22 participants at risk;n=20 participants at risk
subjects received placebo for 1 year Placebo weekly
Vascular disorders
deep venous thrombosis
5.0%
1/20 • Number of events 1 • Adverse events collected during course of study, which lasted 6 years.
0.00%
0/20 • Adverse events collected during course of study, which lasted 6 years.

Other adverse events

Adverse event data not reported

Additional Information

Maria Coco, MD

Montefiore Medical Center

Phone: 718-920-4136

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place